OncoSil Secures $8M Capital Raise Backed by Pengana and Directors
OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.
- Capital raise of $8 million via $6 million placement and $2 million entitlement offer
- Strong backing from cornerstone investor Pengana and company directors
- German G-BA clinical trial to start in first half of 2026 involving 40 hospitals
- Expansion momentum in Spain, Italy, and Turkey with growing hospital adoption
- Pro-forma cash balance of $12 million to support clinical, regulatory, and commercial milestones
Capital Raise to Fuel Growth
OncoSil Medical Limited (ASX, OSL), a medical device company specialising in targeted cancer treatments, has announced a capital raising of approximately $8 million. The raise comprises a $6 million placement to sophisticated investors and a fully underwritten $2 million entitlement offer to existing shareholders. This funding injection is designed to bolster OncoSil’s balance sheet and support key clinical trials, regulatory approvals, and commercial expansion plans throughout 2026.
Focus on German Market and Clinical Trials
A major highlight of OncoSil’s strategy is the upcoming German government-sponsored clinical trial, expected to commence recruitment in the first half of 2026. The trial, backed by Germany’s Federal Joint Committee (G-BA), will involve around 40 hospitals and is anticipated to generate trial revenues of $5.6 million. Additionally, treatments for patients ineligible for the trial are expected to contribute $6.5 million in commercial revenues from these hospitals. This initiative is pivotal, as data from the trial will underpin future reimbursement submissions across other European markets including the UK, France, BENELUX, and the Nordics.
Expanding European Footprint
Beyond Germany, OncoSil is gaining traction in Southern Europe and Turkey, with a growing number of implanting centres in Spain, Italy, and Turkey. Fifteen hospitals in these regions are consistently re-ordering the OncoSil device, signalling strong commercial momentum. The company also anticipates label expansion for its device in combination with FOLFIRINOX chemotherapy in the second half of 2026, which could further broaden its market reach.
Financial Position and Use of Funds
Following completion of the capital raise, OncoSil expects a pro-forma cash balance of approximately $12 million. These funds will be allocated to completing clinical trials, advancing manufacturing capabilities at its Macquarie Park facility, investing in sales and marketing, and supporting market access initiatives. The company’s board and key management are also participating in the placement, committing $150,000, demonstrating confidence in the company’s strategic direction.
Looking Ahead
OncoSil’s roadmap for 2026 includes several important milestones, full data releases from the TRIPP FFX and OSPREY clinical trials in the first half of the year, regulatory submissions and anticipated approvals for label expansions in the second half, and ongoing validation of manufacturing processes. These developments, combined with the German trial and expanding European presence, position OncoSil to potentially reshape treatment options for pancreatic cancer patients across multiple markets.
Bottom Line?
OncoSil’s $8 million capital raise sets the stage for a critical year of clinical progress and European market expansion.
Questions in the middle?
- Will the German G-BA trial recruitment meet its ambitious target of 40 hospitals?
- How will reimbursement outcomes from the German trial influence broader European market access?
- What impact will the label expansion with FOLFIRINOX chemotherapy have on OncoSil’s commercial uptake?
